Equities research analysts expect Strongbridge Biopharma plc (NASDAQ:SBBP) to post earnings per share (EPS) of ($0.34) for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Strongbridge Biopharma’s earnings. The lowest EPS estimate is ($0.36) and the highest is ($0.32). Strongbridge Biopharma posted earnings of ($0.33) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 3%. The business is expected to report its next quarterly earnings results on Thursday, May 9th.

On average, analysts expect that Strongbridge Biopharma will report full-year earnings of ($1.09) per share for the current fiscal year, with EPS estimates ranging from ($1.11) to ($1.07). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.88) per share, with EPS estimates ranging from ($0.97) to ($0.79). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Strongbridge Biopharma.

SBBP has been the subject of several research analyst reports. Laidlaw initiated coverage on shares of Strongbridge Biopharma in a report on Tuesday, December 18th. They issued a “buy” rating and a $11.00 price objective for the company. ValuEngine downgraded shares of Strongbridge Biopharma from a “buy” rating to a “hold” rating in a report on Monday, February 4th. Oppenheimer set a $15.00 price objective on shares of Strongbridge Biopharma and gave the stock a “buy” rating in a report on Tuesday, February 26th. Cantor Fitzgerald set a $12.00 price objective on shares of Strongbridge Biopharma and gave the stock a “buy” rating in a report on Tuesday, February 26th. Finally, TheStreet raised shares of Strongbridge Biopharma from a “d-” rating to a “c-” rating in a report on Tuesday, February 26th. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. Strongbridge Biopharma presently has an average rating of “Buy” and an average target price of $13.39.

In other Strongbridge Biopharma news, major shareholder Associates L.L.C. Cdk purchased 49,397 shares of the business’s stock in a transaction on Thursday, December 27th. The stock was bought at an average cost of $3.99 per share, with a total value of $197,094.03. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 4.20% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Alps Advisors Inc. lifted its holdings in Strongbridge Biopharma by 25.1% in the 3rd quarter. Alps Advisors Inc. now owns 82,657 shares of the biotechnology company’s stock valued at $401,000 after acquiring an additional 16,574 shares during the last quarter. Stifel Financial Corp acquired a new stake in Strongbridge Biopharma in the 4th quarter valued at about $73,000. California Public Employees Retirement System acquired a new stake in Strongbridge Biopharma in the 2nd quarter valued at about $185,000. Citadel Advisors LLC acquired a new stake in Strongbridge Biopharma in the 3rd quarter valued at about $157,000. Finally, Essex Investment Management Co. LLC lifted its holdings in Strongbridge Biopharma by 13.9% in the 4th quarter. Essex Investment Management Co. LLC now owns 494,375 shares of the biotechnology company’s stock valued at $2,215,000 after acquiring an additional 60,214 shares during the last quarter. 56.78% of the stock is owned by institutional investors.

SBBP stock opened at $5.33 on Tuesday. The stock has a market capitalization of $291.38 million, a P/E ratio of 17.19 and a beta of 0.22. Strongbridge Biopharma has a fifty-two week low of $3.82 and a fifty-two week high of $9.25.

About Strongbridge Biopharma

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.

Recommended Story: Price to Earnings Ratio (PE) Basics

Get a free copy of the Zacks research report on Strongbridge Biopharma (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.